Clinical trials of biosimilars should become more similar.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018
   Pooled it
2. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Rheumatology (Oxford, England) · 2017
   Trial
3. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?Drugs · 2021
   Review
4. SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience.Mediterranean journal of rheumatology · 2019
   Review
5. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.The oncologist · 2018
   Review
6. [Revised version of the statement by the DGRh on biosimilars-update 2017].Zeitschrift fur Rheumatologie · 2018
   Article
7. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change".Nature reviews. Rheumatology · 2017
   Article
8. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.mAbs
   Review

Corrections and comments

• Comment on
  A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.2017
• Comment on
  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.2017
• Comment on
  A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as